5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Ind-Swift Laboratories Ltd.

•
indswiftlabs.comBSE: 532305NSE: INDSWFTLAB
Market Cap₹ 3,358 Cr.
Current Price
High / Low₹ 404 / 87
Stock P/E57.0
Book Value₹ 170
Price to Book0.53
Dividend Yield0.00 %
ROCE25.2 %
ROE25.5 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Company has a good return on equity (ROE) track record: 3 Years ROE 31.3%
  • Company has a healthy return on capital (ROCE) of 31.1%
  • Latest quarter profit grew 201.0% YoY, showing strong momentum
  • Company comfortably covers its interest (91.5x coverage)
  • Institutional investors have been accumulating - FII+DII up 5.7pp

CONS

  • Company is loss-making at the operating / net level
  • Operating cash flow has been negative in recent years
  • Receivables are growing faster than sales - a possible quality concern
  • Recent results are weak - TTM profit is down 87.1% versus prior year
  • A large part of profit comes from other income (30.8% of PBT)
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.05x)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.INDSWFTLAB386.1058.573357.590.0024.68181.33191.4525.3524.2417.52
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
299270276517144139122150148150149173186
239207222430146136122158145148144152161
Operating Profit60635487-13-1-93252025
OPM %20.01%23.46%19.63%16.87%-0.88%1.96%-0.77%-5.81%2.08%1.46%3.61%11.75%13.45%
677458511716216151822-38
Interest2021213101010-27121-21
Depreciation14131420666777988
Profit before Tax313627523344-12261011181232
Tax %45.18%17.49%19.03%6.17%0.00%0.00%-0.00%3.56%17.40%20.80%38.99%-27.47%24.62%
Net Profit173022491344-121889111524
2.895.093.6683.045.120.66-0.1332.421.181.101.321.792.81

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
6396757287247528579881,1521,227550659
532570602599611676794930977563606
Operating Profit107105127125141180194222250-1353
OPM %16.70%15.56%17.41%17.29%18.76%21.07%19.60%19.28%20.37%-2.35%8.03%
11724130362341743230445
Interest10690359210710096925131
Depreciation858887104908713157532431
Profit before Tax-83-562959-201687957726473
Tax %29.20%29.30%38.34%34.53%-6.27%127.29%171.41%46.37%27.55%3.05%19.13%
Net Profit-59-401839-21-4-64241825659
EPS0.000.000.000.000.00-0.74-0.977.1970.8137.25—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
-2%
5 Years:
-6%
3 Years:
-18%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
—
3 Years:
—

STOCK PRICE CAGR

10 Years:
26%
5 Years:
40%
3 Years:
64%
1 Year:
256%

RETURN ON EQUITY

10 Years:
6%
5 Years:
18%
3 Years:
31%
Last Year:
25%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

No bonus data found

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital41454548595959595969
4734784965425855795736168631,021
1,2509988321,058974949904794636
Trade Payables1299511711612712416319364110
288400412703748549781141
Total Liabilities2,1812,0151,9011,8341,7821,7581,7531,7581,0731,377
1,0991,0329249018437386275855271
Capital Work in Progress786162134119800
26393939265511185166269
3563443173173433544144280107
00000000107160
Cash & Bank2114629910910426413
600524552536557590582643369157
Total Assets2,1812,0151,9011,8341,7821,7581,7531,7581,0731,377

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
809371-78123135136182-180-39
Cash from Investing-30-31-17-2-10-103-14-104-110
Cash from Financing-48-69-62100-133-124-140-16870074
3-7-823-201-11416-75

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
42.0142.0042.0040.9440.9439.5039.5042.9942.93
1.270.650.463.074.2714.8014.3313.8810.70
0.940.940.940.910.910.680.680.000.17
Government0.000.000.000.000.000.000.000.000.00
55.8056.4156.6055.0753.8745.0245.5043.1246.20

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-06
Copy of Newspaper Publication

2026-09-06 - Ind-Swift Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-05
Shareholders meeting

2026-09-05 - Ind-Swift Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026.

2026-09-04
Copy of Newspaper Publication

2026-09-04 - Ind-Swift Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-04
General Updates

2026-09-04 - Outcome of Preferential Issue Committee meeting held on Friday, 4th September, 2026, as per Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2026-09-02
Outcome of Board Meeting

2026-09-02 - Ind-Swift Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on September 02, 2026.

2026-08-28
Spurt in Volume

2026-08-28 - Significant increase in volume has been observed in Ind-Swift Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Ind-Swift Laboratories Limited has submitted their response.

2026-08-27
General Updates

2026-08-27 - Ind-Swift Laboratories Limited has informed the Exchange about Company's Clarification on Spurt in Volume

2026-08-26
Spurt in Volume

2026-08-26 - Significant increase in volume has been observed in Ind-Swift Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

2026-08-20
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-20 - Ind-Swift Laboratories Limited has informed the Exchange about Transcript of Earning Call held on August 17, 2026

News

Recent coverage and analyst commentary for INDSWFTLAB

Loading news…

🤖

AI Stock Analyst

Ind-Swift Laboratories Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login